Logo image of LIFE.OL

LIFECARE ASA (LIFE.OL) Stock Fundamental Analysis

OSL:LIFE - Euronext Oslo - NO0013355859 - Common Stock - Currency: NOK

7.7  -0.76 (-8.98%)

Fundamental Rating

3

Taking everything into account, LIFE scores 3 out of 10 in our fundamental rating. LIFE was compared to 58 industry peers in the Health Care Equipment & Supplies industry. LIFE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, LIFE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LIFE had negative earnings in the past year.
LIFE had a negative operating cash flow in the past year.
LIFE had negative earnings in each of the past 5 years.
LIFE had a negative operating cash flow in each of the past 5 years.
LIFE.OL Yearly Net Income VS EBIT VS OCF VS FCFLIFE.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

LIFE's Return On Assets of -40.81% is on the low side compared to the rest of the industry. LIFE is outperformed by 82.76% of its industry peers.
With a Return On Equity value of -53.10%, LIFE is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -40.81%
ROE -53.1%
ROIC N/A
ROA(3y)-37.79%
ROA(5y)-33.73%
ROE(3y)-49.85%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
LIFE.OL Yearly ROA, ROE, ROICLIFE.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

LIFE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIFE.OL Yearly Profit, Operating, Gross MarginsLIFE.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
LIFE has more shares outstanding than it did 1 year ago.
LIFE has less shares outstanding than it did 5 years ago.
The debt/assets ratio for LIFE has been reduced compared to a year ago.
LIFE.OL Yearly Shares OutstandingLIFE.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
LIFE.OL Yearly Total Debt VS Total AssetsLIFE.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

A Debt/Equity ratio of 0.12 indicates that LIFE is not too dependend on debt financing.
LIFE has a Debt to Equity ratio of 0.12. This is in the better half of the industry: LIFE outperforms 79.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.04%
LIFE.OL Yearly LT Debt VS Equity VS FCFLIFE.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

LIFE has a Current Ratio of 6.02. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
LIFE's Current ratio of 6.02 is amongst the best of the industry. LIFE outperforms 100.00% of its industry peers.
A Quick Ratio of 6.02 indicates that LIFE has no problem at all paying its short term obligations.
LIFE's Quick ratio of 6.02 is amongst the best of the industry. LIFE outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 6.02
Quick Ratio 6.02
LIFE.OL Yearly Current Assets VS Current LiabilitesLIFE.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

LIFE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.53%.
The Revenue for LIFE has decreased by -40.88% in the past year. This is quite bad
LIFE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.29% yearly.
EPS 1Y (TTM)-97.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
Revenue 1Y (TTM)-40.88%
Revenue growth 3Y34.4%
Revenue growth 5Y30.29%
Sales Q2Q%-50.37%

3.2 Future

Based on estimates for the next years, LIFE will show a decrease in Earnings Per Share. The EPS will decrease by -4.66% on average per year.
The Revenue is expected to grow by 48.57% on average over the next years. This is a very strong growth
EPS Next Y-41.93%
EPS Next 2Y-5.07%
EPS Next 3Y16.13%
EPS Next 5Y-4.66%
Revenue Next Year50%
Revenue Next 2Y50%
Revenue Next 3Y95.74%
Revenue Next 5Y48.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LIFE.OL Yearly Revenue VS EstimatesLIFE.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
LIFE.OL Yearly EPS VS EstimatesLIFE.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIFE. In the last year negative earnings were reported.
Also next year LIFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIFE.OL Price Earnings VS Forward Price EarningsLIFE.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIFE.OL Per share dataLIFE.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

LIFE's earnings are expected to grow with 16.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.07%
EPS Next 3Y16.13%

More info and screens

0

5. Dividend

5.1 Amount

LIFE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFECARE ASA

OSL:LIFE (5/28/2025, 7:00:00 PM)

7.7

-0.76 (-8.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-27 2024-08-27/bmo
Earnings (Next)N/A N/A
Inst Owners4.45%
Inst Owner ChangeN/A
Ins Owners2.61%
Ins Owner ChangeN/A
Market Cap122.05M
AnalystsN/A
Price Target36.72 (376.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.33
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-4.77
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.27
OCFYN/A
SpS0.83
BVpS4.19
TBVpS3.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.81%
ROE -53.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.79%
ROA(5y)-33.73%
ROE(3y)-49.85%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.35%
Cap/Sales 9.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.02
Quick Ratio 6.02
Altman-Z N/A
F-Score2
WACC8.04%
ROIC/WACCN/A
Cap/Depr(3y)499.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)167.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28%
EPS Next Y-41.93%
EPS Next 2Y-5.07%
EPS Next 3Y16.13%
EPS Next 5Y-4.66%
Revenue 1Y (TTM)-40.88%
Revenue growth 3Y34.4%
Revenue growth 5Y30.29%
Sales Q2Q%-50.37%
Revenue Next Year50%
Revenue Next 2Y50%
Revenue Next 3Y95.74%
Revenue Next 5Y48.57%
EBIT growth 1Y-104.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-115.62%
EBIT Next 3Y-4%
EBIT Next 5Y-15.28%
FCF growth 1Y-58.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.74%
OCF growth 3YN/A
OCF growth 5YN/A